SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc.

Mallards over the 30 percent farm-raised DNA threshold are showing poor migration habits The author's drake mallard and three ...

Myriad Genetics, Inc. (MYGN), a genetic and genomic tumor testing and precision medicine provider, and INTERLINK Care Management, ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc. announced ...

Datar Cancer Genetics (DCG) has launched the Target-MRD blood test, designed for the identification and monitoring of molecular residual disease (MRD) in individuals with solid organ cancers.

SALT LAKE CITY - Myriad Genetics , Inc. (NASDAQ: NASDAQ:MYGN), a company specializing in genetic testing and precision medicine with annual revenues of $824 million, has announced the issuance of two ...

Datar Cancer Genetics (DCG), a global leader in non-invasive cancer diagnostics, announces Dr. Massimo Cristofanilli as ...

In a recent study, Mass General Brigham researchers demonstrated that through low-cost genetic samples that can be obtained from a cheek swab or blood test, they can improve identification of people ...

It’s tough for a man to know what to do following a diagnosis of prostate cancer.The treatment is often worse than the ...

Shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) have earned a consensus recommendation of “Hold” from the fourteen analysts that are covering the company, MarketBeat reports. Three ...

21, 2025 /PRNewswire/ -- Datar Cancer Genetics (DCG) today announced the launch of Target-MRD, an advanced molecular residual disease (MRD) monitoring blood test for solid organ cancers.